Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
reverse merger
Biotech
Werewolf transforms into Ambros via reverse merger
Werewolf’s hunt for strategic alternatives has ended with a deal that positions Ambros to take its lead candidate through to a filing for approval.
Nick Paul Taylor
Aug 21, 2026 9:50am
Slate uses Fulcrum to join Nasdaq with $245M for migraine trials
Aug 17, 2026 9:30am
Caldera hits Nasdaq via Synlogic reverse merger
Jul 29, 2026 8:56am
Scancell heads to Nasdaq via reverse merger with Neuphoria
Jul 23, 2026 10:13am
Scancell bids for Nasdaq-listed Neuphoria to raise US profile
Jun 29, 2026 7:55am
Spurned by FDA, Passage Bio finds exit through Remix
Jun 24, 2026 5:20pm
